Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase - Hughes, Timothy; Saglio, Giuseppe; Branford, Susan; Soverini, Simona; Kim, Dong-Wook; Müller, Martin C.; Martinelli, Giovanni; Cortes, Jorge; Beppu, Lan; Gottardi, Enrico; Kim, Dongho; Erben, Philipp; et al. (Journal of clinical oncology, 2009)
Keywords: Antineoplastic Agents - therapeutic use; Australia; Benzamides; Biological and medical sciences; Chromosome aberrations; Drug Resistance, Neoplasm - genetics; Europe; Fusion Proteins, bcr-abl - antagonists & inhibitors; Fusion Proteins, bcr-abl - genetics; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Korea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Medical genetics; Medical sciences; Mutation; ORIGINAL REPORTS; Piperazines - therapeutic use; Protein Kinase Inhibitors - therapeutic use; Pyrimidines - therapeutic use; Time Factors; Treatment Outcome; Tumors; United States; Australia; United States; Europe; Korea; Chromosomal aberration; Human; Nilotinib; Enzyme; Tyrosine kinase inhibitor; Transferases; Non-specific serine/threonine protein kinase; Chronic myelogenous leukemia; Malignant hemopathy; Philadelphia chromosome; Myeloproliferative syndrome; Abnormal chromosome C9; Cancerology; bcr gene; C-Onc gene; Abnormal chromosome G22; Abnormal chromosome; Genetics; Mutation; Hybrid gene; Cancer; Chromosome translocation